Cargando…

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could provide survival benefits for locally advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). However, the role of radical surgery for EGFR-TKI treated stage IIIB EGFRm NSCLC remains controversial. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Yicheng, Bian, Dongliang, Huang, Zhida, Yu, Huansha, Huang, Jie, Zhang, Peng, He, Wenxin, Liu, Hongcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909294/
https://www.ncbi.nlm.nih.gov/pubmed/36776292
http://dx.doi.org/10.3389/fonc.2023.1034897
_version_ 1784884543620120576
author Xiong, Yicheng
Bian, Dongliang
Huang, Zhida
Yu, Huansha
Huang, Jie
Zhang, Peng
He, Wenxin
Liu, Hongcheng
author_facet Xiong, Yicheng
Bian, Dongliang
Huang, Zhida
Yu, Huansha
Huang, Jie
Zhang, Peng
He, Wenxin
Liu, Hongcheng
author_sort Xiong, Yicheng
collection PubMed
description BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could provide survival benefits for locally advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). However, the role of radical surgery for EGFR-TKI treated stage IIIB EGFRm NSCLC remains controversial. This study attempted to assess the feasibility of neoadjuvant EGFR-TKI followed by radical surgery for stage IIIB EGFRm NSCLC. PATIENTS AND METHODS: Between 2013 and 2020, EGFRm lung adenocarcinoma (LUAD) patients in clinical stage IIIB undergoing neoadjuvant EGFR-TKI followed by surgery (T-S-Arm) and EGFR-TKI alone (T-Arm) were reviewed retrospectively in Shanghai Pulmonary Hospital (SPH). The chi-square test, Student’s t-test or Fisher’s exact test was performed for analysis of baseline characteristics. Progression-free survival (PFS) was estimated using the Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify independent predictors of progression. RESULTS: A total of 43 patients were divided into T-S-Arm (n = 21) and T-Arm (n = 22). Patients were well-balanced between the two arms. The majority of patients were female (n = 25, 58.1%), non-smokers (n = 35, 81.4%), first-generation of EGFR-TKI treatment (n = 39, 90.7%), and exon 19 deletions (19-DEL) (n = 26, 60.5%). The median diagnostic age was 63.0 years [interquartile range (IQR), 54.0-67.5 years). At the cut-off date with June 30th 2022, median follow-up time was 28 months (IQR, 20-39 months). Neoadjuvant EGFR-TKI treatment followed by radical surgery could significantly improve the median PFS compared with patients underwent EGFR-TKI alone (23.0 months vs 14.5 months, P = 0.002). Multivariate Cox regression analysis demonstrated that radical surgery (T-S-Arm vs. T-Arm, HR: 0.406; 95% CI: 0.207-0.793, P = 0.027) was the only independent predictor for disease progression. The stratified analysis demonstrated patients with N2 disease could benefit from radical surgery (HR, 0.258; 95% CI, 0.107-0.618), especially for patients harboring L858R mutation (HR, 0.188; 95% CI, 0.059-0.604). CONCLUSIONS: For stage IIIB EGFRm NSCLC patients, the prognosis might be improved by neoadjuvant EGFR-TKI followed by radical surgery versus EGFR-TKI alone, especially for those with N2 disease and harboring L858R mutation.
format Online
Article
Text
id pubmed-9909294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99092942023-02-10 The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center Xiong, Yicheng Bian, Dongliang Huang, Zhida Yu, Huansha Huang, Jie Zhang, Peng He, Wenxin Liu, Hongcheng Front Oncol Oncology BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could provide survival benefits for locally advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). However, the role of radical surgery for EGFR-TKI treated stage IIIB EGFRm NSCLC remains controversial. This study attempted to assess the feasibility of neoadjuvant EGFR-TKI followed by radical surgery for stage IIIB EGFRm NSCLC. PATIENTS AND METHODS: Between 2013 and 2020, EGFRm lung adenocarcinoma (LUAD) patients in clinical stage IIIB undergoing neoadjuvant EGFR-TKI followed by surgery (T-S-Arm) and EGFR-TKI alone (T-Arm) were reviewed retrospectively in Shanghai Pulmonary Hospital (SPH). The chi-square test, Student’s t-test or Fisher’s exact test was performed for analysis of baseline characteristics. Progression-free survival (PFS) was estimated using the Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify independent predictors of progression. RESULTS: A total of 43 patients were divided into T-S-Arm (n = 21) and T-Arm (n = 22). Patients were well-balanced between the two arms. The majority of patients were female (n = 25, 58.1%), non-smokers (n = 35, 81.4%), first-generation of EGFR-TKI treatment (n = 39, 90.7%), and exon 19 deletions (19-DEL) (n = 26, 60.5%). The median diagnostic age was 63.0 years [interquartile range (IQR), 54.0-67.5 years). At the cut-off date with June 30th 2022, median follow-up time was 28 months (IQR, 20-39 months). Neoadjuvant EGFR-TKI treatment followed by radical surgery could significantly improve the median PFS compared with patients underwent EGFR-TKI alone (23.0 months vs 14.5 months, P = 0.002). Multivariate Cox regression analysis demonstrated that radical surgery (T-S-Arm vs. T-Arm, HR: 0.406; 95% CI: 0.207-0.793, P = 0.027) was the only independent predictor for disease progression. The stratified analysis demonstrated patients with N2 disease could benefit from radical surgery (HR, 0.258; 95% CI, 0.107-0.618), especially for patients harboring L858R mutation (HR, 0.188; 95% CI, 0.059-0.604). CONCLUSIONS: For stage IIIB EGFRm NSCLC patients, the prognosis might be improved by neoadjuvant EGFR-TKI followed by radical surgery versus EGFR-TKI alone, especially for those with N2 disease and harboring L858R mutation. Frontiers Media S.A. 2023-01-26 /pmc/articles/PMC9909294/ /pubmed/36776292 http://dx.doi.org/10.3389/fonc.2023.1034897 Text en Copyright © 2023 Xiong, Bian, Huang, Yu, Huang, Zhang, He and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xiong, Yicheng
Bian, Dongliang
Huang, Zhida
Yu, Huansha
Huang, Jie
Zhang, Peng
He, Wenxin
Liu, Hongcheng
The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
title The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
title_full The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
title_fullStr The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
title_full_unstemmed The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
title_short The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
title_sort efficacy of neoadjuvant egfr-tki therapy combined with radical surgery for stage iiib lung adenocarcinoma harboring egfr mutations: a retrospective analysis based on single center
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909294/
https://www.ncbi.nlm.nih.gov/pubmed/36776292
http://dx.doi.org/10.3389/fonc.2023.1034897
work_keys_str_mv AT xiongyicheng theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT biandongliang theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT huangzhida theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT yuhuansha theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT huangjie theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT zhangpeng theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT hewenxin theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT liuhongcheng theefficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT xiongyicheng efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT biandongliang efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT huangzhida efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT yuhuansha efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT huangjie efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT zhangpeng efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT hewenxin efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter
AT liuhongcheng efficacyofneoadjuvantegfrtkitherapycombinedwithradicalsurgeryforstageiiiblungadenocarcinomaharboringegfrmutationsaretrospectiveanalysisbasedonsinglecenter